- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06668324
Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation (MS-PEKOS)
September 15, 2025 updated by: Novartis Pharmaceuticals
Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation (MS-PEKOS)
The study aims to compare the experiences, including injection-related reactions (IRRs) of patients newly receiving ofatumumab to those starting to receive ocrelizumab SC formulation
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
134
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
East Hanover, New Jersey, United States, 07936
- Novartis Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients with MS who are prescribed and initiating OMB or OCR SC and who are living in the US at the time of the survey will be invited to participate following a referral from their healthcare providers
Description
Inclusion Criteria:
- Ability to use a mobile device or computer with broadband internet access (or data streaming available)
- Ability to read, understand, and respond in English
- Adult aged 18 years of age or over at the time of the survey
- Self-confirmed diagnosis of MS
- Prescribed either OMB or OCR SC and will receive their first injection (Day 0) followed by completing the study survey between Day 1 and Day 7
Exclusion Criteria:
- Participated in an OMB or OCR randomized clinical trial
- Previously treated with OMB or OCR SC
- Cognitive impairment that impacts the patient's ability to participate in a survey study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
ofatumumab
|
|
ocrelizumab SC formulation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of patients reported local injection-related reaction post first injection
Time Frame: Day 1- 7 post first injection, at the time of survey completion
|
Proportion of patients reported local injection-related reactions (including pain, erythema, induration, and pruritus) by using modified Defense and Veterans Pain Rating Scale (DVPRS)
|
Day 1- 7 post first injection, at the time of survey completion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of patients in a 5-Likert scale for satisfaction on injection-related experience (post first injection)
Time Frame: Day 1 - 7 post first injection, at the time of survey completion
|
Proportion of patients in a 5-Likert scale (extremely dissatisfied, dissatisfied, neutral, satisfied, and extremely satisfied) for satisfaction on injection-related experience
|
Day 1 - 7 post first injection, at the time of survey completion
|
|
Proportion of patients reported local injection-related reaction post second injection
Time Frame: Day 1- 7 post second injection, at the time of survey completion
|
Proportion of patients reported local injection-related reactions (including pain, erythema, induration, and pruritus) by using modified Defense and Veterans Pain Rating Scale (DVPRS)
|
Day 1- 7 post second injection, at the time of survey completion
|
|
Proportion of patients in a 5-Likert scale for satisfaction on injection-related experience (post second injection)
Time Frame: Day 1- 7 post second injection, at the time of survey completion
|
Proportion of patients in a 5-Likert scale (extremely dissatisfied, dissatisfied, neutral, satisfied, and extremely satisfied) for satisfaction on injection-related experience
|
Day 1- 7 post second injection, at the time of survey completion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 15, 2024
Primary Completion (Actual)
September 5, 2025
Study Completion (Actual)
September 5, 2025
Study Registration Dates
First Submitted
October 22, 2024
First Submitted That Met QC Criteria
October 30, 2024
First Posted (Actual)
October 31, 2024
Study Record Updates
Last Update Posted (Estimated)
September 19, 2025
Last Update Submitted That Met QC Criteria
September 15, 2025
Last Verified
May 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- COMB157AUS25
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.